#glp-1-therapies

[ follow ]
#obesity #access-and-affordability #production-capacity #novo-nordisk #pharma-competition #drug-innovation
Public health
fromwww.theguardian.com
2 days ago

WHO says weight loss drugs are new chapter' in fight against obesity

GLP-1 weight-loss drugs can help millions reduce obesity and its harms, but production, pricing and safety (pregnancy contraindication) limit equitable global access.
Healthcare
fromFortune
3 weeks ago

Novo Nordisk wants to keep its crown leading the weight loss drugs pack-despite outlook downgrades and lawsuits, its CFO has a plan | Fortune

Novo Nordisk faces declining sales and stock after GLP-1 competition; success depends on launching new products like Wegovy pill, CagriSema, and amycretin.
from24/7 Wall St.
3 months ago

Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions

Eli Lilly (NYSE:LLY) has quickly emerged as one of Wall Street's biggest winners, fueled by explosive demand for its new generation of weight-loss and diabetes treatments. The company's GLP-1 drugs, including Mounjaro and the newly approved Zepbound, have turned into blockbuster products, generating billions in sales and reshaping the pharmaceutical landscape. As a result, Eli Lilly's stock surged more than 50% year-to-date in 2024.
Healthcare
[ Load more ]